This is a promotional website developed by AstraZeneca and intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk.
- For you
- For your patients
Resources for you
TRUQAP
CAPItello-291 summary
Hear from leading breast cancer experts,
Dr Sacha Howell and Prof Rebecca Bowen,
who discuss how TRUQAP plus fulvestrant
has shown to improve PFS vs placebo plus
fulvestrant for patients with HR+/HER2-
negative aBC who have one or more
PIK3CA/AKT1/PTEN alterations, following
recurrence or progression on, or after,
an ET ± CDK4/6i.
Efficacy and safety
profile summary
Find out more about the efficacy and safety profile of TRUQAP plus fulvestrant in this resource, which explores and summarises key findings from the CAPItello-291 trial.
Dosing, monitoring and management
Managing cutaneous adverse drug reactions guide
Discover practical guidance on
managing TRUQAP-associated cutaneous
adverse drug reactions in patients with
HR+/HER2-negative aBC, along with key
findings from the CAPItello-291 trial,
information on assessing AE severity
and dermatologist-recommended
management strategies.
Dosing support guide
Explore clear guidance on TRUQAP
dosing, modifications and AE management,
designed to help you offer your eligible patients an optimised treatment regimen.
Genomic testing
Biomarker testing guide
Read a comprehensive overview of
biomarker testing in HR+/HER2-negative
aBC, including the role of NGS from
diagnosis to treatment recommendations.
You can also find advice on sample types,
when to test and how to interpret and
discuss results with your patients.
Genomic testing factsheet
Learn more about detecting
PIK3CA/AKT1/PTEN alterations in HR+/
HER2-negative aBC, with best practice
guidance for when, how and where to
perform genomic testing.
Genomic testing flashcard
Refresh your understanding of why, when
and how to test patients for PIK3CA/AKT1/
PTEN alterations with this summary sheet.
Resources for your patients
Patient booklet
This booklet is designed to reassure
patients and let them know that there is
support available throughout the treatment
journey. It includes information (in patient-
friendly language) about their treatment,
dosing guidance and advice on managing
adverse events.
Dosing card
This handy wallet-sized card reminds
patients of their dosing schedule and
can be used as a visual aid to support their
conversations with different
healthcare professionals.
GB-68388 | April 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.